🔎 Trials Near Me

ホーム › 子宮内膜がん › フロリダ州

フロリダ州における子宮内膜がんの臨床試験

フロリダ州内の拠点で、子宮内膜がんに関する65件の研究が参加者を募集しています。

フロリダ州内の都市

公式研究テキスト(英語)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • UM Sylvester Comprehensive Cancer Center at Aventura, Aventura
  • UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach
  • 他6件
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • University of Miami - Sylvester Comprehensive Cancer Center, Miami
  • Advent Health, Orlando
  • Florida Cancer Specialists South, Port Charlotte
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  • Sarasota Memorial Hospital-Venice, N. Venice
  • Florida Cancer Specialists - Sarasota Downtown, Sarasota
  • FPG - Surgical Oncology Clinics Gynecologic Oncology Surgery, Sarasota
  • 他3件
被験者募集中第3相
18歳以上 · 女性 · 2026/10/02更新 · NCT07198074

A Phase 1 Study of the Safety and Tolerability of CTX-10726

  • Mayo Clinic Florida, Jacksonville
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07419841

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus, Fort Myers
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  • AdventHealth Cancer Institute, Orlando
被験者募集中第1相
19歳以上 · 全性別 · 2026/10/01更新 · NCT06586957

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • AdventHealth Medical Group Oncology Research at Celebration, Kissimmee
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  • Mayo Clinic, Jacksonville
  • Genoma Research, Inc., Miami
  • Orlando Health, Orlando
  • 他1件
被験者募集中観察研究
18歳以上 · 女性 · 2026/09/29更新 · NCT05051722

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Sarasota
  • Avenzo Therapeutics Recruiting Site, Tampa
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05867251

DESTINY-PANTUMOUR04

  • Research Site, Coral Springs
  • Research Site, St. Petersburg
  • Research Site, West Palm Beach
被験者募集中観察研究
18歳〜130歳 · 全性別 · 2026/09/25更新 · NCT07124000

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

  • Research Site, Jacksonville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06218914

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance

  • University of Miami, Miami
被験者募集中第2相
18歳以上 · 女性 · 2026/09/24更新 · NCT07594015

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

  • UM Sylvester Comprehensive Cancer Center at, Deerfield Beach
  • UM Sylvester Comprehensive Cancer Center at Doral, Doral
  • University of Florida, Gainesville
  • 他9件
被験者募集中第2相
18歳以上 · 女性 · 2026/09/24更新 · NCT05640999

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • Florida Cancer Specialists, Sarasota
  • Moffitt Cancer Center and Research Institute, Tampa
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  • Moffitt, Tampa
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07114601

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

  • Omnicure Clinical Research, Doral
  • Bioresearch Partner, Hialeah
  • Florida Clinical Trials Group, Plantation
  • 他1件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07262619

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

  • Sylvester Comprehensive Cancer Center, Miami
  • Sara Cannon Research Institute Lake Nona, Orlando
  • Hematology - Oncology Associates of the Treasure Coast, Port Saint Lucie
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  • Florida Cancer Specialists - South ( Site 7003), Fort Myers
  • UF Health Davis Cancer Pavilion and Shands Med Plaza ( Site 6026), Gainesville
  • Mount Sinai Braman Comprehensive Cancer Center ( Site 6031), Miami Beach
  • 他3件
被験者募集中第3相
18歳以上 · 女性 · 2026/09/17更新 · NCT06952504

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • Florida Cancer Specialists - Lake Nona, Orlando
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07109726

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  • Broward Health Medical Center, Fort Lauderdale
被験者募集中第3相
18歳以上 · 女性 · 2026/09/17更新 · NCT06340568

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • Memorial Healthcare System, Hollywood
  • The Oncology Institute of Hope & Innovation, Lakeland
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • University of Miami, Miami
  • Sarah Cannon Research Institute - Lake Nona Florida, Orlando
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

  • SMH - Sarasota - Main Campus, Sarasota
  • Women's Care - 9th Ave, St. Petersburg
  • Women's Care - Armenia Ave, Tampa
被験者募集中第3相
18歳以上 · 女性 · 2026/09/09更新 · NCT07166094

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

  • Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
被験者募集中第1相
18歳以上 · 女性 · 2026/09/03更新 · NCT07755436

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  • Research Site, Fort Myers
  • Research Site, Miami
  • Research Site, Miami Beach
  • 他4件
被験者募集中第3相
18歳以上 · 女性 · 2026/09/03更新 · NCT06989112

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

  • Florida Cancer Specialists, Orlando
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/27更新 · NCT07186842

Endometrial Cancer Vaginal Fluid Specimen Collection Study

  • Physical Care Clinical Research, Sarasota
被験者募集中観察研究
18歳以上 · 女性 · 2026/08/27更新 · NCT07544680

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

  • SCRI FCS Sarasota, Sarasota
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/27更新 · NCT07227168

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

  • H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., Tampa
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/26更新 · NCT07383506

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • Moffitt Cancer Center, Tampa
被験者募集中第1相
15歳以上 · 全性別 · 2026/08/25更新 · NCT06276491

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

  • Mount Sinai Comprehensive Cancer Center, Miami Beach
被験者募集中第2相
18歳以上 · 女性 · 2026/08/21更新 · NCT05548296

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

  • Mayo Clinic in Florida, Jacksonville
被験者募集中第1/2相
16歳以上 · 全性別 · 2026/08/20更新 · NCT05269381

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

  • SCRI - Florida Cancer Specialists, Sarasota
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07470853

FOG-001 in Locally Advanced or Metastatic Solid Tumors

  • Mayo Clinic, Jacksonville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05919264

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • AdventHealth Celebration, Celebration
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626

Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

  • Miami Cancer Institute Baptist Health South Florida, Miami
  • ADVENTHEALTH (Data collection only), Orlando
被験者募集中観察研究
18歳以上 · 女性 · 2026/08/07更新 · NCT04291612

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • USOR Florida Cancer Specialists South, Fort Myers
  • USOR Florida Cancer Specialists North, St. Petersburg
  • USOR Florida Cancer Specialists East, West Palm Beach
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

  • University of Miami, Miami
被験者募集中第1相
18歳以上 · 女性 · 2026/08/03更新 · NCT05603910

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Florida Cancer Specialists, Fort Myers
  • Mayo Clinic (Florida), Jacksonville
  • Cancer Specialists of North Florida, Jacksonville
  • 他2件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT04657068

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。